TRIANA Biomedicines
TRIANA Biomedicines Raises $120 million in Series B
TRIANA Biomedicines Raises $120 million in Series B
TRIANA Biomedicines has successfully raised $120 million in a Series B at a Undisclosed led by Ascenta Capital.
Company Overview
TRIANA Biomedicines is a Biotechnology company headquartered in Lexington MA, founded in 2019 with 100+ employees.
TRIANA Biomedicines is developing molecular glue degrader therapies targeting cancer. Their lead product candidate TRI-611 is a molecular glue degrader for ALK+ non-small cell lung cancer demonstrating potential as a next-generation precision oncology treatment.
Fundraising Details
- Amount Raised: $120 million
- Round Type: Series B
- Valuation: Undisclosed
- Date: 2025-12-03
- Investors: Ascenta Capital and Bessemer Venture Partners and YK Bioventures and Regeneron Ventures and Invus and Finchley Healthcare Ventures and RA Capital Management and Atlas Venture and Lightspeed Venture Partners and Pfizer Ventures
About TRIANA Biomedicines
TRIANA Biomedicines is developing molecular glue degrader therapies targeting cancer. Their lead product candidate TRI-611 is a molecular glue degrader for ALK+ non-small cell lung cancer demonstrating potential as a next-generation precision oncology treatment. The company is positioned in the Biotechnology sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Lexington MA
- Founded: 2019
- Team Size: 100+
- Industry: Biotechnology
What This Means
This funding round demonstrates strong investor confidence in TRIANA Biomedicines's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The Biotechnology sector continues to attract significant investment as companies innovate to meet evolving market demands. TRIANA Biomedicines's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching Undisclosed marks an important milestone for TRIANA Biomedicines, positioning the company among notable players in the Biotechnology industry.
Looking Ahead
With this new capital, TRIANA Biomedicines is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotechnology space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2025-12-03. For more information about TRIANA Biomedicines, visit their headquarters at Lexington MA.
Company Info
Investors (10)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free